143 related articles for article (PubMed ID: 27398937)
1. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma.
Lassaletta A; Guerreiro Stucklin A; Ramaswamy V; Zapotocky M; McKeown T; Hawkins C; Bouffet E; Tabori U
Pediatr Blood Cancer; 2016 Nov; 63(11):2038-41. PubMed ID: 27398937
[TBL] [Abstract][Full Text] [Related]
2. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
3. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
Gnekow AK; Kortmann RD; Pietsch T; Emser A
Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
[TBL] [Abstract][Full Text] [Related]
4. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
[TBL] [Abstract][Full Text] [Related]
5. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
[TBL] [Abstract][Full Text] [Related]
6. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
Grossauer S; Koeck K; Murphy NE; Meyers ID; Daynac M; Truffaux N; Truong AY; Nicolaides TP; McMahon M; Berger MS; Phillips JJ; James CD; Petritsch CK
Oncotarget; 2016 Nov; 7(46):75839-75853. PubMed ID: 27713119
[TBL] [Abstract][Full Text] [Related]
7. [Targeted therapies with BRAF inhibitors for pediatric low- and high-grade gliomas with BRAFv600e mutation. Prof. Dr. Juan P. Garrahan Hospital experience].
Warriner E; Fernández Ponce N; Freytes C; Sampor C; Oller A; Rugilo C; Lubieniecki F; Vazquez V; Alderete D; Baroni LV
Medicina (B Aires); 2021; 81(5):791-799. PubMed ID: 34633954
[TBL] [Abstract][Full Text] [Related]
8. Sarcoid-like reaction in a child following prolonged therapeutic exposure to dabrafenib and trametinib for BRAF V600E mutated hypothalamic/chiasmatic glioma.
Wilhelmsson M; Chun FJ; Yeung RSM; Krtizinger F; McKeown T; Coblentz A; Ertl-Wagner B; Tabori U; Bartels U; Das A
Pediatr Blood Cancer; 2023 Nov; 70(11):e30619. PubMed ID: 37555268
[No Abstract] [Full Text] [Related]
9. Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies.
Wagner LM; Myseros JS; Lukins DE; Willen CM; Packer RJ
Pediatr Blood Cancer; 2018 May; 65(5):e26917. PubMed ID: 29369501
[TBL] [Abstract][Full Text] [Related]
10. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma.
Zhukova N; Rajagopal R; Lam A; Coleman L; Shipman P; Walwyn T; Williams M; Sullivan M; Campbell M; Bhatia K; Gottardo NG; Hansford JR
Cancer Med; 2019 Jan; 8(1):40-50. PubMed ID: 30569607
[TBL] [Abstract][Full Text] [Related]
11. Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition.
Bavle A; Jones J; Lin FY; Malphrus A; Adesina A; Su J
Pediatr Hematol Oncol; 2017 May; 34(4):254-259. PubMed ID: 29040023
[TBL] [Abstract][Full Text] [Related]
12. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.
Dodgshun AJ; SantaCruz N; Hwang J; Ramkissoon SH; Malkin H; Bergthold G; Manley P; Chi S; MacGregor D; Goumnerova L; Sullivan M; Ligon K; Beroukhim R; Herrington B; Kieran MW; Hansford JR; Bandopadhayay P
J Neurooncol; 2016 Jun; 128(2):293-302. PubMed ID: 26994902
[TBL] [Abstract][Full Text] [Related]
13. BRAF-Targeted Therapy in the Treatment of
Johanns TM; Ansstas G; Dahiya S
J Natl Compr Canc Netw; 2018 Apr; 16(4):451-454. PubMed ID: 29632063
[No Abstract] [Full Text] [Related]
14. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging treatment strategies for children with progressive chiasmatic-hypothalamic glioma diagnosed as infants: a web-based survey.
Azizi AA; Schouten-van Meeteren AYN
J Neurooncol; 2018 Jan; 136(1):127-134. PubMed ID: 29071540
[TBL] [Abstract][Full Text] [Related]
16. Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis.
Gorodezki D; Zipfel J; Queudeville M; Sosa J; Holzer U; Kern J; Bevot A; Schittenhelm J; Nägele T; Ebinger M; Schuhmann MU
J Neurooncol; 2022 Dec; 160(3):567-576. PubMed ID: 36319795
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of centrally located low-grade glioma in children.
Terashima K; Chow K; Jones J; Ahern C; Jo E; Ellezam B; Paulino AC; Okcu MF; Su J; Adesina A; Mahajan A; Dauser R; Whitehead W; Lau C; Chintagumpala M
Cancer; 2013 Jul; 119(14):2630-8. PubMed ID: 23625612
[TBL] [Abstract][Full Text] [Related]
19. Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens.
Ishi Y; Hatanaka KC; Yamaguchi S; Fujita H; Motegi H; Kobayashi H; Terasaka S; Houkin K
Brain Tumor Pathol; 2017 Oct; 34(4):165-171. PubMed ID: 28836232
[TBL] [Abstract][Full Text] [Related]
20. Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children.
Howden K; Chapman S; Serletis D; Kazina C; Rafay MF; Faury D; Hazrati LN; Jabado N; Vanan MI
Cureus; 2021 Nov; 13(11):e19400. PubMed ID: 34926002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
